Tecentriq combo again meets PFS endpoint in Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) said first-line treatment with Tecentriq atezolizumab plus chemotherapy met the co-primary endpoint of improving progression-free survival (PFS) vs. chemotherapy alone in the Phase III IMpower132 trial to treat stage IV non-squamous non-small cell lung cancer (NSCLC). The company said a significant improvement on the second co-primary endpoint of overall survival (OS) was not shown at the study's interim analysis, and that the trial will continue as planned. Final OS data are expected next year.

The open-label, international trial enrolled 578 chemotherapy-naïve patients to receive 1,200 mg IV Tecentriq every three weeks plus Alimta and investigator’s choice of cisplatin or carboplatin or chemotherapy alone during an induction period of four or six cycles. Patients with clinical benefit during the induction phase received maintenance treatment with Tecentriq plus Alimta or Alimta alone, respectively, until disease progression...